Hauptinhalt

Forschungsschwerpunkt

Growth factor signaling

Development of novel gene targeting strategies based on RNAi/siRNAs, ribozymes

Polyethylenimine (PEI)-based nanoparticles for the therapeutic in vivo delivery of small RNA molecules

Functional analysis of various growth factors and receptors, relevant in tumor growth and tumor angiogenesis

    (e.g., HER-1/EGFR, HER-2/erbB2, FGF-BP, PTN, ALK, Pim-1)

Development of novel treatment strategies based on the specific knockdown of pathologically relevant genes

Ausgewählte Publikationen

  • A sensitive polymerase chain reaction-based method for detection and
    quantification of metastasis in human xenograft mouse models.
    Malek A, Catapano CV, Czubayko F, Aigner A.
    Clin Exp Metastasis. (2010) 27:261-71.
  • RNAi-mediated gene-targeting through systemic application of
    polyethylenimine (PEI)-complexed siRNA in vivo.
    Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A.
    Gene Ther. (2005) 12:461-6.
  • Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo.
    Aigner A, Renneberg H, Bojunga J, Apel J, Nelson PS, Czubayko F.
    Oncogene. (2002) 21:5733-42.
  • A secreted FGF-binding protein can serve as the angiogenic switch in human cancer.
    Czubayko F, Liaudet-Coopman ED, Aigner A, Tuveson AT, Berchem GJ, Wellstein A.
    Nat Med. (1997) 3:1137-40
-